Seres Therapeutics(MCRB) - 2025 Q2 - Quarterly Results

Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital ...